Immunotherapy & Melanoma Bridge 2017 just ended. We’ve made an assessment of the congress with Bernard A. Fox of the Laboratory of Molecular and Tumor Immunology of Oregon Health and Science University. We are living exciting times in certain fields of oncology and Fox explained us why.
It’s becoming increasily clear that many or most patients lack a destructive anti-cancer immune response.
BERNARD A. FOX
Laboratory of Molecular and Tumor Immunology Oregon Health and Science University
Napoli, 1 dicembre 2017 Intervista a cura di Giulia Volpe